Error message
Notice: Undefined index: content in _drupal_default_html_head() (line 345 of /var/www/vhosts/rovi.es/httpdocs/includes/common.inc).
|
Date |
Title |
Description |
PDF |
|
10 May 2023 |
On P&L |
The Company releases the first quarter 2023 financial results presentation
|
Download |
|
10 May 2023 |
On P&L |
The Company releases the press release related to the first quarter 2023 financial results
|
Download |
|
25 Apr 2023 |
On business and financial situation |
ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE)
|
Download |
|
21 Feb 2023 |
On business and financial situation |
The Company releases the full year 2022 financial results presentation.
|
Download |
|
21 Feb 2023 |
On business and financial situation |
The Company releases the press release related to the full year 2022 financial results.
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
03 Nov 2023 |
Share buy-back , stabilisation and treasury stock programmes |
Share Buyback Program: transactions conducted between 27 October and 2 November 2023
|
Download |
|
27 Oct 2023 |
Share buy-back , stabilisation and treasury stock programmes |
Share Buyback Program: transactions conducted between 20 October and 26 October 2023
|
Download |
|
20 Oct 2023 |
Share buy-back , stabilisation and treasury stock programmes |
Share Buyback Program: transactions conducted between 13 October and 19 October 2023
|
Download |
|
13 Oct 2023 |
Share buy-back , stabilisation and treasury stock programmes |
Share Buyback Program: transactions conducted between 6 October and 12 October 2023
|
Download |
|
06 Oct 2023 |
Share buy-back , stabilisation and treasury stock programmes |
Share Buyback Program: transactions conducted between 29 September and 5 October 2023
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
04 Apr 2019 |
Liquidity contracts and specialists |
Liquidity contract: transactions conducted in the first quarter of 2019
|
Download |
|
19 Mar 2019 |
R&D: new licenses, patents and registered trademarks |
ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia
|
Download |
|
26 Feb 2019 |
Informe Anual de Remuneraciones de los Consejeros |
ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors
|
Download |
|
26 Feb 2019 |
Informe Anual de Gobierno Corporativo |
ROVI releases the 2018 Annual Corporate Governance Report
|
Download |
|
26 Feb 2019 |
Otros sobre gobierno corporativo |
The Company informs about the agreements adopted by the Board of Directors
|
Download |
Pages
